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ABSTRACT

Shamili Sammohi, M.S. Department of Pharmacology and Toxicology, Wright State
University, 2015. Effect of Progesterone, Terbutaline and Leptin on the function of
alveolar type – II cells.

The “surfactant” produced by type II pneumonocytes is deficient in term and preterm
infants born and diagnosed with Respiratory Distress Syndrome (RDS). Corticosteroids
such as dexamethasone or betamethasone are clinically used as the primary line of
treatment to stimulate the production of surfactant. The steroidal hormone, progesterone
appears to play a role in the fetal lung development and also appears to increase the
expression of inflammatory markers in both term and preterm infants. However, the
impact of progesterone on surfactant production remains unknown. Like progesterone,
the tocolytic drug terbutaline has also been implicated in phosphatidylcholine production
in the pneumonocytes of the human lung. Interestingly, recent reports indicate that leptin,
a hormone mainly produced by adipocytes may increase surfactant production in-vitro.
However, other authors could not reproduce those results. This study was designed to
analyze the long-term effect of progesterone, terbutaline and leptin on surfactant
production in-vitro, either alone or in combination with betamethasone as a positive
control. As a model, we used the human lung cell line NCI-H441. The production and
processing of Surfactant Protein-B (SP-B), in this cell line is almost identical to explant
cultures of fetal lung and cultured type II cells. Biochemical, immunochemical and
molecular approaches, including thin layer chromatography (TLC) and RealTime-PCR
iii

were followed to determine the pharmacological role of progesterone, terbutaline and
leptin on surfactant production. Our experiments indicate that betamethasone increased
lipid secretion and surfactant-B production at 24 hours. Likewise, progesterone and
terbutaline, increased lipid secretion and surfactant production when analyzed by
immunocytochemistry. Betamethasone also increased surfactant production when added
to these tocolytics. RealTime PCR also showed a similar increase in surfactant-B mRNA.
The results suggest that progesterone in combination with betamethasone may improve
surfactant production in high preterm risk patients. However terbulatine and leptin need
further studies on their mechanisms and future use.
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Introduction
Statement of the problem
This study is about specific drugs that are used to treat pregnant women who are
at a risk of delivering their babies before their due dates. According to the World Health
Organization (WHO), preterm birth is defined as the birth prior to 37 complete weeks of
gestation. Based upon the gestational age of the infant, preterm birth is further subdivided
into three categories as; 1) extremely preterm, for infants who are born before 28 weeks
of gestation; 2) very preterm, i.e., 28 – 32 weeks of gestation; and 3) moderate preterm
for infants born between 32 – 37 weeks of gestation (1). Although there are numerous
problems associated to the preterm birth, one of the most common and critical problem is
Respiratory Distress Syndrome (RDS) (2). Infact more than 60% of the preterm births are
seen in Africa and South Asia and 12% of infants are born prematurely when compared
to higher income countries (1). For instance, in developed countries such as the US and
UK, premature births along with RDS occur in 1 – 2 % of the total pregnancies each year
(2, 5). In contrast, developing countries such as India and Pakistan have a much higher
rates of premature infant births of 10 – 50% (3, 4). The risk of neurosensory disability
and risk of death escalates, with a decrease in gestational age (especially infants born
between 26-28 weeks of gestation) (5, 6, 7). A reliable diagnostic tool to predict the risk
of preterm birth is not yet available. Therefore, the main treatment has been to try to
delay birth for up to 48 hours, which would allow time to administer specific drugs to
1

help mature the lungs and prevent RDS. To delay birth, there are several drugs that act to
slow the contractions of the uterus and delay preterm birth for 1 or 2 days. This additional
time is often sufficient for the administration of corticosteroids, which helps in the
maturation of lungs potentially allowing the premature infant to breathe properly soon
after its birth. However, scientific studies have not been carried out on the effect that
these drugs have on surfactant and lipid production in lung cells. This study was designed
to determine if these drugs have an impact on lipid and surfactant production in lung
cells.

Respiratory distress syndrome
RDS in preterm infants is characterized by a lack of surfactant. Without enough
surfactant, the lungs collapse and the infant has to work harder to breathe (8). The infant
might not be able to breathe in enough oxygen to support the body’s organs and the lack
of oxygen (hypoxic condition) may cause damage to the brain and other organs if proper
treatment is not provided immediately. The primary treatment when a preterm birth is
likely is to give dexamethasone or betamethasone to accelerate the expression of
surfactant (9, 10, 11). The duration of treatment can be for 24 hours or 48 hours
depending upon the type of corticosteroid prescribed. The common regimen
recommended by the NIH Consensus Development Panel (9) in 1995 for betamethasone
was; 2 doses of 12 mg given intramuscularly 24 hours apart and 6mg of dexamethasone
given intramuscularly in 4 doses 12 hours apart for each dose. In-order to determine if
this dose is high enough to cause adverse effects (10), the NIH panel in 2000 met again
after randomized control trials were performed at different regions of the world and
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concluded that there was no evidence for the adverse effects of the drug and suggested to
continue the same regime for 7 days for those who are at risk for preterm delivery (9, 10).
Type II alveolar cells, especially pneumonocytes are very specialized cells that
produce and secrete lipids and surfactant, which are responsible for maintaining the
stability and function of the lungs. During the first breath of the infant, a considerable
force is necessary to overcome the high viscosity and inertia of the fetal lung fluid that is
filled in the alveolar sacs during birth (8). Due to the high pressures generated by the first
breath, they aid in moving the lung’s fluid from the sacs and the formation of an airliquid interface. As the air enters, the reduction in size of airways at the periphery causes
an increase in surface tension at the air-liquid interface (8). Presence of an adequate
surfactant maintains the stability of lungs by lowering the surface tension at the junction.
As the alveolar surfactant is produced after 30 weeks of gestation, most of the preterm
births are leading to RDS and finally to the death of some of those infants, due to the lack
of surfactant production.

Surfactant
Surfactant is a form of ‘detergent’ encased into small cellular packets called
lamellar bodies (13), mostly produced by specialized lung cells called Type II
pneumonocytes. Surfactant helps lungs to inflate and deflate by lowering the surface
tension on the cell surface inside the lung (12), thus aids in stabilizing the alveoli during
respiration (15). Surfactant is synthesized as a complex mixture of lipoproteins
containing 70-80% phospholipids, 8–10% protein, and 10% neutral lipids in which
lecithin or dipalmitoyl phosphatidylcholine (DPPC), is the main phospholipid component
(2). By predominantly possessing the phospholipid fraction, lecithin, the surfactant is
3

believed to be a lipoprotein (15). In addition, phosphatidylglycerol makes up 4–15% of
the phospholipids, although it is not necessary for the lung function, but it has been used
as a marker for detecting the fetal lung maturity (2).

Surfactant Production
The components of pulmonary surfactant are synthesized in the endoplasmic
reticulum (ER) of Type II alveolar cells and transported through the Golgi apparatus to
secretory vesicles where they are packed and stored in lamellar bodies (13, 14), as
represented in figure 1 below. After these granules are discharged into the liquid lining of
the alveolus, the surfactant phospholipids act to form a complex lattice called tubular
myelin (13). The surfactant production is considered a cyclic process in which the
phospholipid in the lumen is moved in and out of the Type II alveolar cell and reused up
to 10 times before being degraded (2). The surfactant phospholipids and proteins are
taken back subsequently into Type II cells, by an endosomal pathway in the form of small
vesicles and are transported into lamellar bodies for storage and further recycling. After
they are secreted, the lamellar bodies unwind to form bipolar monolayers of phospholipid
molecules. This process depends upon two important apoproteins; SP-B and SP-C (13).
Phospholipid provides the material which is used to form a monolayer at the air-liquid
interphase to lower the surface tension inside the alveolar type – II cells, which is
produced from tubular myelin. The tubular myelin depends on surfactant-B for
performing its functions and stores surfactant in it.

4

Figure 1: Surfactant metabolism in type II alveolar cells (Pneumonocytes) which has
been modified from Whitsett et al., 1994 and 1996 (16, 17, 20)

Surfactant proteins B and C (SP-B and SP-C)
There are four surfactant proteins produced in the lungs: Surfactant Protein–A
(SP-A), Surfactant Protein-B (SP-B), Surfactant Protein–C (SP-C) and Surfactant
Protein–D (SP-D). Among these, hydrophilic proteins, SP-A and SP-D possess
considerable similarities in the sequence of their proteins (81) and also play a role in
innate immune responses especially inside the lung (82). On the other hand SP-B and SPC proteins are similar in nature and function (18, 19, 20). Surfactant protein B (SP-B)
and SP-C are small hydrophobic proteins (9 kDa) that are responsible for 2-4% of the
surfactant mass (18, 19). SP-B starts as a ~40 kDa pro-protein that is cleaved to become a
~9-kd protein in the type II alveolar cells just before entering the lamellar bodies (20, 19).
5

SP-B has been shown to mediate rapid absorption and spreading of DPCC as a monolayer
to the air- liquid (alveolar air-fluid) interface in vivo during expiration (18).

Role of Surfactant Protein – B in Type II Cells
It has been shown that the activity of SP-B is necessary for rapid film formation
by phospholipid mixtures. Also, that even though the surfactant consists of both
hydrophilic and hydrophobic proteins, it is the hydrophobic proteins that most likely have
a major role in determining the surface-active properties of the surfactant (21). SP-B and
the phospholipid dipalmitoylphosphatidylcholine (DPPC), commonly known as lecithin,
helps to lower the surface tension of the lung so that breathing can occur (18). Secretion
of the pulmonary surfactant by type II pneumonocytes is considered to be a rate-limiting
step in delivering the surfactant to the air-liquid interface which eventually helps in
lowering the surface tension inside the lung, which largely depends on SP-B (18).

Importance of maintaining surface tension in alveolar type II cells
In most of the species, certain lining cells of the terminal respiratory units
undergo alterations allowing them to be distinguished as Type II pneumonocytes during
the last 10-20% of gestation (22-26 weeks of gestation) (22). Due to the absence of
surface tension lowering surfactant, alveoli become unstable at low volume and tend to
collapse. In addition, some of the smaller alveoli get emptied into larger ones to equalize
pressure between two of them, which may even be dangerous for the newborn to breathe
properly. The high pressures generated in the first few breaths of the newborn are not
only required for expansion, but also crucial in moving the lung liquid for establishing an
6

air-liquid interface (23). During this process, the surface tension at the junction of lung
fluid with air increases and the clearance of fluid from smaller airways may be more
efficient in the presence of adequate surfactant. Due to the lack of an adequate amount of
surfactant, newborns with RDS are highly prone to death.

Phospholipids (Lecithin/DPCC and Sphingomyelin) and their ability to
predict RDS
The lung is known to be an active site of lipid synthesis due to the process of
incorporation

of

acetate

into

fatty

acids

and

phospholipids.

Lecithin,

i.e.,

phosphatidylcholine, is the major fatty acid that is incorporated into phospholipids (24).
The amount of lecithin and the proportion of palmitic acid are increased dramatically in
the fetal lung along with gestational age, suggesting that these increases could be closely
related to the development of surface activity of the lung. Sphingomyelin is also a
phospholipid that aids in surfactant production. An alveolar lecithin/sphingomyelin ratio
of less than 2 is a reliable predictor of RDS in premature infants and a noticeable increase
in lecithin content of the fetal lung is considered as a characteristic feature of pulmonary
maturation (25). Fetal lung maturity is measured by counting the lamellar bodies. At ~3233 weeks of gestation, the concentration of lecithin in the amniotic fluid begins to
escalate almost constantly until term, whereas the concentration of sphingomyelin
remains relatively constant and hence, the ratio of these lipids, lecithin and
sphingomyelin provides an estimation of the amount of surfactant being produced (26,
27). Therefore, the prevailing dogma is that RDS is most often due to a developmental
deficiency of pulmonary surfactant along with an immature lung function, which is
similar to the condition of premature birth where all the surfactant components are
7

decreased (28, 29). This is not unexpected as fetuses do not normally have a need for a
mature lung while in utero, as it is very early for the birth of infant.

Analyzing SP-B protein for an overall surfactant increase
SP-B plays a critical role in the formation of lamellar bodies within Type II cells
(30), which are the absolute requirements for processing, storage, secretion and normal
function in-vivo (31) and to facilitate the fusion of multivesicular bodies, also by assisting
with a proper assembly of the lamellar structure of lipids. These are the fundamental
reasons for selecting SP-B as the key protein for estimating the surfactant production in
this project. Surfactant-B is a 10-kb SP-B gene which is located on chromosome 2, that
encodes a 2.2-kb messenger RNA (mRNA) gives rise to 40-kD pre-pro SP-B (20, 19) and
which is processed by both the amino and carboxyl regions to result an 8-kD mature SPB. This mature SP-B is highly lipophilic and is packaged along with surfactant
phospholipids in the lamellar bodies of alveolar type II cells (14). The absence of SP-B
would lead to an accumulation of multivesicular bodies along with the formation of
disorganized and unfinished lamellar structures, which further aids in producing
membranous vesicles (29). This defective formation and secretion of lamellar bodies in
the absence of SP-B can also delay the normal accumulation of phospholipid and
surfactant proteins in amniotic fluid according to a reported case study of Hamvas, A et al
(32).

NCI-H441 cells
Aside from primary cells cultured from living tissue, there are no fetal or infant
lung cell lines available for this type of research. Primary cells from fetuses and infants
8

are also not readily available. Therefore, we have used the human adenocarcinoma NCIH441 cell line obtained from ATCC, which has been used for other similar projects.
Vidaeff et al (33) has suggested that the NCI-H441 cell line has been very useful for
investigating the regulation of surfactant components in previous studies on
dexamethasone over extended periods of time frame, i.e. 7-8 days. The synthesis and
processing of SP-B in this cell line has been reported to be very similar to the explant
cultures of fetal lung and also to the cultured isolated type II cells (34). Hence, the H441
cell line has proven to be useful for studying the surfactant protein expression and
production of these proteins, which are of importance clinically in the diagnosis and
therapy of various pulmonary disorders.

In a study screening 33 human lung

adenocarcinomas, only NCI-H441 cells were found to synthesize and secrete both SP-B
in significant abundance, which were not detected in the A549 adenocarcinoma line (34).
These cells were also shown to respond to the multiple regulatory factors that influence
SP-B expression in a similar manner as observed in human type II pneumonocytes (35).

Betamethasone (Positive control in this study)
Corticosteroids, i.e., dexamethasone and betamethasone, have been shown to play
a role in stimulating the synthesis of surfactant in the alveolar Type II cells in-vivo in the
fetal lamb (36) and are still the most popularly used corticosteroids in clinical practice
today for stimulating the surfactant production and lung metabolism. Although there is
similar efficacy of both of dexamethasone and betamethasone on reducing the risk of
RDS, the reduction in mortality rate was significantly higher with betamethasone versus
dexamethasone (48% vs 11%) (37). The maximum stimulatory effect of fetal lung with
betamethasone has been observed at 10-7 mol/L (35), which is the same concentration we
9

used in our study. The glucocorticoids (GC) usually binds at the glucocorticoid receptor
(GR), although certain areas of the receptor shows a fundamental similarity with other
steroidal hormones for their easy binding (38). Glucocorticoid responsive elements
(GRE’s) are present in the promotor regions of steroid-responsive genes (39, 67). It is
believed to have both positive responses, i.e., transcriptional activation of the gene and
negative responses, i.e., causes suppression of the gene with this binding at particular
regions of the gene (38). This process is mediated by direct binding of GC-GR complex
to GRE, which results to show some conformational changes in the DNA. The interaction
of this complex also increases binding of other transcriptional factors such as activating
protein-1 or nuclear factor kappa- beta (NFK- β) (40). In a premature rabbit model of
human RDS, combined therapy with antenatal corticosteroids and intratracheal natural
surfactant has given a superior result than the therapy alone with corticosteroids (41). Our
study is designed to test some of these drugs with betamethasone.

Tocolytics
Tocolytics are the most common medication used to suppress or delay the preterm
labor by causing anti-contractions of the uterine muscle. The therapy also gives time for
the administration of betamethasone, which greatly accelerates fetal lung maturity, but
takes one to two days to work. We have chosen two drugs that are often used to delay
contractions and mature lungs in conjugation with betamethasone. The two drugs selected
for this reason are progesterone and terbutaline. In addition, we are also interested to
observe the effect drug leptin may have on the lungs, as these are the ports of leptin
receptor in the fetal lungs. Also, to observe the effects of this peptide hormone, if it plays
a role in the metabolism and secretion of lipids or surfactant.
10

Progesterone
Progesterone is a steroidal hormone supplied by the placenta during fetal
development. Previous studies on the expression of progesterone and estrogen receptors
have indicated that both of these may play a role in fetal lung development (43, 44). This
is achieved by the suppression of calcium-calmodulin-myosin light chain kinase system
through a process of reducing the calcium influx into the epithelial membrane and
altering the resting potential of smooth muscle (45). The combined use of 17-β Estradiol
and progesterone has shown to enhance the expression of surfactant proteins involved in
the primary embryonic lung cells (43). The supply of these hormones are shown to be
disrupted in the extreme preterm infant when compared to the term infant (42), which
gives an impression that the lack of supply of hormone progesterone, which is necessary
for maintenance of lung functioning and uterine contractions in preterm fetus may be an
important factor for causing preterm birth. This led us to a new way of investigating the
presence of progesterone in alveolar type II cells for the secretion and production of
surfactant and also phospholipids when treated alone or in combination with
betamethasone.

Terbutaline sulfate
Terbutaline sulfate, a β-2 adrenergic receptor agonist is used to treat patients
suffering from asthma and some other respiratory diseases. Terbutaline sulfate has been
shown to slow or attenuate contractions of the uterus, and thus is used as a tocolytic to
delay the preterm birth (47). However, due to some adverse effects like increase in the
maternal heart rate, changes in maternal diastolic blood pressure from the baseline,
intraventricular hemorrhage and slight trauma observed by using this drug (71), its use
11

has been limited to 24 – 48 hours to delay the preterm birth according to the regulations
provided by the US and the Institute of Medicine (US). Keeping those guidelines in view,
we have chosen this drug to measure the surfactant increase in this study only for 24 –
48hrs of drug treatment. β- Adrenergic receptor agonists aid breathing problems by
raising the levels of intracellular cyclic AMP (48, 49) causing an increase in the
surfactant secretion by type II cells in-vitro. It has been already shown that terbutaline
along with 3- isobutyl-1-methylxanthine (IBMX) stimulated surfactant secretion from
alveolar type II cells. It has also been shown that these drugs increase the secretion of one
of the major lipids responsible for the surfactant production, phosphatidylcholine (also
called as lecithin) (50). It has also been approved that this drug terbutaline sulfate could
be tested for the secretion of surfactant in-vitro and also in-vivo (51). Terbutaline has
been studied to be efficacious and a more reliable drug for treating preterm labor than
some of the drugs like nifedipine and salbutamol (72). Hence, one of the goals of this
project was to examine the lung cells response to terbutaline sulfate either alone or in
combination with betamethasone for determining its role in surfactant or lipid production
and secretion.

Leptin
The peptide hormone, leptin is produced by the adipose tissue and placental
trophoblast and has been suggested to regulate various aspects of human fetal
development (52). It is believed that leptin acts through both autocrine and/or paracrine
mechanisms, and it may also be an important factor in the maintenance of pregnancy
itself (53, 54). Leptin binds to the leptin receptor (Leprec) which is present in the lung
epithelium during antenatal and neonatal development periods, as it is present in many
12

tissues (55). The specific receptor for leptin is a member of the cytokine class I receptor
superfamily, which is found to possess multiple existing isoforms (56). Leptin binds the
Lep-R isoform that is present in the epithelium of type-II pneumonocytes and thus aids in
inducing the expression of the major pulmonary surfactant proteins SP-A, SP-B and SP-C
which are responsible for surfactant production (57). A shorter isoform (LEP-Rs) of leptin
which is predominantly found in the peripheral tissues, such as lung, helps in contributing
to leptin signaling by utilizing a mitogen-activated protein kinase (MAP-K) (58).
Recently, animal studies have shown that leptin may also be involved in the regulation of
the embryonic lung growth and maturation. In addition, antenatal administration of leptin
resulted in an increase in the number and size of pulmonary cells in the newborn, which
indicates that there is also an improvement in the development of lungs by enlarging the
alveolar size and surface area (18, 59). Furthermore, leptin and its receptor have been
identified in the type II pneumonocytes of fetal mice and have been co-related with an
increase in production of surfactant-related protein in these cells when they were
stimulated with leptin externally (60). From these experiments, a high level expression of
the functional leptin receptor and also the detection of its splice variants in the fetal lungs
altogether suggests that the specific binding for leptin in these cells (53, 60, 61). Some
recent studies have indicated that a lack of exposure to leptin in late pregnancy, i.e., the
point at which type-II alveolar epithelial cells mature and produce surfactant, would be
subsequently responsible for contributing to RDS and Fetal Growth Restriction (18, 62).
Previous studies have shown that administration of betamethasone to these type of
cells aid in upregulating the putative fibroblast pneumocyte factor in the lung
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concomitant with an increase in lecithin in preterm infants (63, 64, smith 65) and also an
up-regulation of placental leptin receptor protein in pregnant rat (66)

14

Development of Hypothesis:
Previous research has shown that betamethasone is a potent stimulator of lipid and
surfactant secretion in alveolar type II cells. However, there are few studies showing a
direct and combinational effects of tocolytics on surfactant and lipid secretion. The goal
of this study was to identify the response of progesterone, terbutaline or leptin alone or in
combination with betamethasone on human lung cells that secrete surfactant or lipid. To
achieve this goal, we will test the hypothesis that betamethasone alone stimulates lipid
production and secretion. Furthermore we propose that the tocolytics progesterone,
terbutaline and peptide hormone leptin will also stimulate surfactant-B production and
lipid secretion and that betamethasone will augment their effects. The hypothesis will be
tested using immunochemical staining of cells for surfactant-B; thin layer
chromatographic analysis of lipids and western blotting for cellular surfactant-B and
leptin receptor protein. RealTime PCR analysis will be used to determine the effect of
these drugs on surfactant-B expression at 24 hours and 48 hours following treatment.

Specific aims
Aim 1: To show that the administration of betamethasone causes an increase in surfactant
production in human lung cells
Aim 2: Test the hypothesis that Terbutaline or progesterone increase surfactant
production and lipid secretion from NCI-H441 cells

15

Aim 3: Test the hypothesis that leptin increases surfactant production and lipid secretion
from NCI-H441 cells

16

Materials and methods
Experimental design

Figure 2: Experimental Design Part I

Figure 3: Experimental Design Part II

17

Table 1: Drugs and their concentrations used in the project
Drugs Used

Concentration

Betamethasone

10-7 M

Progesterone

10-6 M

Terbutaline

10-6 M

Leptin

0.1mg/ml

Table 2 above shows the list of drugs and their concentrations used to treat NCI-H441
adenocarcinoma cells used in this project.

Cell culture
The human lung cell line (NCI-H441) obtained from ATCC was originally
derived from patient biopsy samples of a human adenocarcinoma. Since 1982 it has been
extensively used as a transfection host for expression of pulmonary surfactant protein
(32-34, 68). The cells were grown and incubated following the ATCC protocol. Briefly,
NCI-H441 lung cells were grown in Waymouth’s MB571/5 medium (Invitrogen)
containing 10% charcoal-stripped FBS (Hyclone) and 1X antibiotic/antimycotic (Cellgro;
containing 10,000 unit/ml penicillin G sodium, 10,000 µg/ml streptomycin sulfate, and
25 ug/ml amphotericin B). Cells were passaged by trypsin at 70% confluency to a new
flask. After 8 passages (continuous multiplications) of the cells, all of them were
trypsinized and grown into 4 different 12 well plates. After the cells became 70%
confluent inside the wells, drugs were prepared according to their solubility and also the
exact concentration of drug which showed a maximum potency according to clinical use.
As positive control, betamethasone was used at a concentration of 10-7M, which is
also the concentration used by the physicians to treat RDS or other preterm disorders.
This drug was prepared by dissolving 3.92mg of betamethasone in 1ml of ethanol and
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10µl of that solution was added to 990µl of 0.1%BSA (Bovine Serum Albumin) in
Waymouth media. Then 50µl of the sterile drug was added into 49.95ml of media, which
finally made it 10-7M. BSA was added to replace the FBS (Fetal Bovine Serum).
Progesterone was dissolved in ethanol. P8783 progesterone powder suitable for cell
culture, was obtained from Sigma Life Sciences and dissolved with 1ml of absolute
ethanol and 10µl of this solution was mixed with 990µl of 0.1% BSA in Waymouth
media. Of this solution 500µl were added to 49.5ml of the media to finally make a 10-6M
solution. T2528 Terbutaline hemi-sulfate salt was also prepared following the same
procedure except that it was dissolved in distilled water instead of ethanol. L4146 Leptin
– 1mg human was dissolved in 1ml of distilled water and 1µl of this solution was added
to 10ml of the 0.1%BSA which finally made a concentration of 0.1mg/ml. One well was
left without adding any drug and in other wells 1ml of all these drugs have been added
either individually or in combination with the positive control, betamethasone. After
respective time intervals, the media was collected in centrifuge tubes separately and then
150µl of Tris EDTA (TE) buffer was added to the cells and collected into 500µl
centrifuge tubes. All these tubes were neatly labelled and the cells were stored in -80°C
and the media in -80°C. The collected cells and media were used for different
experiments like HPTLC, Western blots and immunostaining.
The pictorial representation of the order of addition of different drugs can be seen
in the image below.
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Terbutaline(T)

Control
Betamethasone(B)

T+B

Progesterone(P)

Leptin(L)

L+B

P+B

Figure 4: Plate scheme for all the experiments. The cell culture plates were set up in this
order for all the experiments where cells were grown for TLC and western blots.

Thin layer chromatography (TLC)
High Performance Thin Layer Chromatography (HPTLC) is used to separate
lipids on a solid phase based on the partition coefficient of lipids in organic solvents. This
technique uses TLC plates with a more uniform and smaller particle size which will give
a higher resolution of lipids with shorter retention times. The media and cells that were
stored in the refrigerator were thawed and then 1ml of the media was added with an equal
amount (1:1) of organic solvents 9:1 chloroform: methanol mixture. Then they were
thoroughly mixed until the aqueous and organic layers separated. The lipids were soluble
in the organic phase, hence the aqueous layer was discarded and the organic phase was
dried by using speed vacuum overnight. After the lipids were mostly dried, 100µl of
methanol was added to the lipids at the bottom of the tube and mixed very thoroughly in
it. Standard sphingomyelin and lecithin (4µl) were spotted on the HPTLC Silica gel 60
F254 plates (Merck KGaA, Billerica, MA) and also TLC Silica gel 60 F254 plates (EMD,
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Gibbstown, NJ) along with aliquots of 4µl of each sample. The lipids were resolved with
an organic solvent system containing chloroform: methanol: acetic acid: acetone: ddH2O
at a 51:32:9:5:3 ratio. As we are already aware that the mobile phase flows through the
stationary phase and carries the components of the mixture with it and different
components travel at different rates. The spots were then seen clearly after the imaging.
The stationary phase here is the silica gel or alumina, often contains a substance which
fluoresces in UV light. When the solvent front has been reached ~0.5 cm from the top of
the HPTLC plate, it was air-dried and sprayed with a mixture of primuline in water at a
concentration of 1 mg/ml and again air-dried. The stock solution of primuline was
prepared by dissolving 100 mg of primuline in 100 ml of water. The spray reagent was
prepared by diluting 1ml of the stock solution in 100 ml of a mixture of acetone/ water
(4/1, by volume). The primuline stained plates were examined under a DyLight 625
setting on the ChemiDoc MP imaging camera (Bio-Rad, Hercules, CA) for 5 seconds and
the image was saved for evaluation. To analyze the bands produced on HPTLC plate, an
ROI box was drawn around each band and the density was integrated for each band in
each treatment. The integrated density was recorded and averaged for all three samples.
Mass spectrometric analysis of the bands was inevitably required for confirmation of the
band’s true identity.

Immunocytochemistry
Cells were plated at a density of ~2000 cells/well in an 8 well Lab-Tek® slide
chamber (Nunc, Naperville, IL) and treated with each of the drugs in the presence or
absence of the positive control, betamethasone and one of the well was left as a control
i.e. without addition of any drug including betamethasone. In order to compare the action
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of these drugs upon the lung cells individually, some of the wells were administered with
betamethasone alone and some with only these drugs to clearly differentiate the action of
these drugs with and without the presence of betamethasone. The cells were fixed for 1
hour with 2% paraformaldehyde (2% PFA), (Electron Microscopy Sciences, Hatfield,
PA) in Phosphate Buffered Saline (PBS). PFA (2%), was added with 0.1% Triton X100
i.e. 100 µl of Triton X100 in 10 ml of PBS after washing thoroughly with 1X PBS. The
solution was removed and washed with 1X PBS 5 times for 5 minutes each. The cells
were then incubated with 100 µl of Mouse Primary antibody, ab 3282 Ms mAb to
Surfactant Protein B (Mature) [SPB02] obtained from Abcam, diluted at 1:250 in 5 ml of
10% goat serum overnight. The primary antibody was washed away 5 times with 1X PBS
for every 5 minutes and the cells were then incubated with Donkey anti-Mouse IgG
coupled to Cy3 [Cy 3- conjugated AffiniPure Donkey Anti-Mouse IgG (H+L) ] obtained
from Jackson ImmunoResearch Laboratories for 2 hours. The secondary antibody was
washed with PBS. The cells were then washed once with deionized water and mounting
was performed by using Prolong Gold Antifade reagent with DAPI obtained from life
technologies (P36931) to stain the nuclei. Stained cells were visualized on a Leica DMR
epifluoresecent microscope and images were captured using a Leica CCD digital camera
system. These images were prepared for publication using Adobe Photoshop and Adobe
Illustrator CC software. Non-stained cells were visualized on a light microscope.

Western blotting
The cells were lysed using a mini-pestle (twisted for about 10 times). This sample
was taken into a fresh Eppendorf tube and added with 20µl of Laemmli Sample Buffer
(Blue SDS Sample Buffer) obtained from Bio-Rad and also 1-2µl of 2-Mercaptoethanol,
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which is the loading buffer obtained from Sigma Chemical Company, St. Louis, MO,
USA. This mixture was boiled for 10 minutes and then added into the wells of
CriterionTM TGXTM Precast Gels obtained from Bio-Rad, along with a standard ladder
(Precision Plus Protein Western CTM Standards obtained from Bio-Rad. After loading the
sample, the proteins were separated by adjusting the volts to 125V and current to 65mA
for an hour approximately.
The main purpose of western blotting was to probe the proteins separated on the
gel using an antibody specific for one of the proteins and for this purpose, the proteins
should be transferred to a thin membrane that allows them to be stabilized for washing,
probing and finally allows the antibody to gain an easy access to the proteins.
Polyvinylidine Difluoride (PVDF) was used as a blotting membrane in this experiment.
For making a gel/PVDF sandwich, the cassette was opened and was dipped into the
transfer buffer poured in a tray. After running the gel to a fixed point (to avoid running of
the proteins until bottom and lose proteins), it was placed in between two blotting pads
which were placed in between the filter papers on both the sides. The PVDF membrane
was activated by soaking it in 50% Methanol for 5 min. It was then placed upon the gel
such that the proteins upon the gel can be transferred on to the PVDF membrane (No air
bubbles should be observed under the PVDF membrane, as that would cause inefficient
or no transfer in that area). Another pre-soaked blotting pad was placed upon it, covered
with a pre-soaked filter paper and slowly close the sandwich with a knob at the top of it.
The whole sandwich was placed in the blotting apparatus such that the membrane was on
to the “positive” side. Transfer buffer was added into the apparatus until the diodes were
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covered. The transfer was set for overnight maintaining the voltage as 50V and current as
100mA.
Next day the membrane was probed with an antibody. The membrane was
blocked to prevent the antibody binding to it via hydrophobic interactions, the membrane
was added with a mixture of 3% non-fat dry milk (0.6mg for 20ml of 1X PBS - Tween
solution), 20ml of PBS and 0.3% Tween into it. This was added to the PVDF membrane
placed in a glass bowl and blocking it for an hour at room temperature with rocking upon
the belly dancer/ rocker. After 1 hour it was washed with 1X PBS – Tween for 10 min.
The mouse primary antibody, ab3282 Ms mAb to Surfactant Protein B(Mature) obtained
from Abcam, diluted at 1:250 was added to 5ml of 1X PBS-Tween for an hour and again
washed with 1X PBS-Tween for 10 min. The secondary antibody, ImmunoPure Antibody
Goat Anti-Mouse IgG HRP obtained from Pierce (Lot#FJ9240713), was administered to
it and placed upon the shaker at least for 30 min. Then washed with 1X PBS – Tween and
1 ml each of substrates, Prod # 1859022 Super Signal West Femto Luminol/Enhancer
solution and Prod # 1859023 Super Signal West Femto Peroxide Buffer were added to
the PVDF membranes. They were then examined under the ChemDoc MP imaging
camera (Bio-Rad, Hercules, CA) for 10 min under Chemi High Sensitivity, Chemi High
Resolution and Chemi for Criterion Gel and the images were saved for evaluation. After
imaging of the protein by probing surfactant – B antibody, it was stripped with the
Restore TM Western Blot Stripping Buffer Prod # 21059 obtained from Thermo Scientific,
Rockford, IL. Then it was washed for some time with the wash buffer, 1X PBS - Tween.
It was blocked by using the blocking buffer of 3% non-fat dry milk in 1X PBS- Tween
solution for an hour. Then it was washed with the wash buffer and added with 1:500

24

dilution (20µl of β- actin in 10 ml of wash buffer) of the β- actin primary antibody {Actin
(H-300) sc- 10731, Lot# L0612 rabbit polyclonal IgG} obtained from Santa Cruz
Biotechnology. It was left to probe for an hour and after washing it with the wash buffer,
it was added with the secondary antibody (Prod # 32260 Pierce Goat Anti-Rabbit PolyHRP) obtained from Thermo Scientific with a dilution of 1: 30,000, i.e. 1µl in 30ml of
1X PBS- Tween solution. It was then washed with wash buffer and 1ml each of the
substrates, Prod # 1859022 Super Signal West Femto Luminol/Enhancer solution and
Prod # 1859023 Super Signal West Femto Peroxide Buffer were added for examining
under the ChemiDOC MP imaging Camera. The molecular weight and density of the
protein added with β- actin antibody and Surfactant – B were analyzed for comparison.

Western blotting for leptin receptor protein
The same procedure was followed for the Leptin Receptor Protein too. After
blocking the PVDF with blocking buffer 3% Non-Fat Dry Milk in 1%PBS- Tween buffer
for an hour, it was washed for 5 minutes with the wash buffer (1%PBS-Tween) and then
probed with L9536 Anti-leptin Receptor Antibody produced in Goat (Lot#SLBH9793V)
obtained from Sigma, 1:250 dilution in 10ml of blocking buffer for an hour. It was then
washed with the wash buffer for 5 minutes and then probed with the Donkey Anti-Goat
Polyclonal Secondary Antibody (Cat#AB6885-1) obtained from Abcam. After washing
with the wash buffer for 5 minutes, it was added with 1 ml each of substrates, Prod #
1859022 Super Signal West Femto Luminol/Enhancer solution and Prod # 1859023
Super Signal West Femto Peroxide Buffer were added to the PVDF membranes and
examined under the ChemDoc MP imaging camera (Bio-Rad, Hercules, CA) for 10 min
under Chemi High Sensitivity, Chemi High Resolution and Chemi for Criterion Gel and
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the best image was saved for evaluation. After imaging of the protein by probing AntiLeptin Receptor antibody, it was stripped with the Restore

TM

Western Blot Stripping

Buffer Prod # 21059 obtained from Thermo Scientific, Rockford, IL. Then it was washed
for some time with the wash buffer, 1X PBS - Tween. It was blocked by using the
blocking buffer of 3% non-fat dry milk in 1X PBS- Tween solution for an hour. Then it
was washed with the wash buffer and added with 1:500 dilution (20µl of β- actin in 10 ml
of wash buffer) of the β- actin primary antibody {Actin (H-300) sc- 10731, Lot# L0612
rabbit polyclonal IgG} obtained from Santa Cruz Biotechnology. It was left to probe for
an hour and after washing it with the wash buffer, it was added with the secondary
antibody (Prod # 32260 Pierce Goat Anti-Rabbit Poly-HRP) obtained from Thermo
Scientific with a dilution of 1: 30,000, i.e. 1µl in 30ml of 1X PBS- Tween solution. It was
then washed with wash buffer and 1ml each of the substrates, Prod # 1859022 Super
Signal West Femto Luminol/Enhancer solution and Prod # 1859023 Super Signal West
Femto Peroxide Buffer were added for examining under the ChemiDOC MP imaging
Camera. The molecular weight and density of the protein added with β- actin antibody
and Anti-Leptin Receptor Antibody were analyzed for comparison.

Protein determination through Bradford assay
The quantification of proteins has been done for the extracted cells treated with
the above mentioned drugs before performing western blotting. Plastic test tubes were
filled with 800, 799,798, 795, 790, 785 and 780 µl of water. Then added with 1, 2, 5, 10,
15 and 20 µl of 1mg/ml BSA standard to each tube and finally with 200 µl of Bio-Rad
Reagent and were vortexed until mixed properly. Then the samples were named as 1, 2,
3, 4, 5, 6, 7, 8 for 24 hour drug treated samples and 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 for
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48 hour drug treated samples. Distilled water (798 µl) was added to each tube, followed
by addition of 2 µl of the sample and 200 µl of Bio-Rad Reagent to each tube. All the
tubes were vortexed thoroughly and then all of the standard and sample aliquots of 200 µl
were added to a 96 well plate for obtaining the results under the Fusion plate reader
within an hour.

RT-qPCR:
As the Real Time PCR Analysis was used to determine the expression levels of
surfactant - B mRNA in the NCI441 cell line treated with the tocolytics, betamethasone
and leptin. The RNA in the samples are quantified and then converted into cDNA by a
process called reverse transcription. Then this cDNA is used as a template for exponential
augmentation of the given template by using PCR.
Before performing the Real Time PCR Analysis, the RNA Extraction was
performed using the Trizol Method. The cell culture was performed as described above
and after 24 and 48 hours of addition of different drugs, the media was collected into
Eppendorf tubes. Trizol reagent (500µl) was added to each in the 12-well plates and
incubated for 5 minutes at room temperature. Then this solution turns a bit viscous as the
cells lyse, releasing RNA which is then collected into 2ml Eppendorf tubes. Chloroform
(200µl) was administered and vortexed until the solution was homogenous. Then it was
centrifuged for 15 min at 13,000 rpm; 40C. After 15 min the tubes were removed very
slowly from the centrifuge so as to avoid mixing of the phases, as we can observe 3
phases, lower red phenol/chloroform phase, a jelly like interphase and colorless upper
phase. The colorless upper aqueous phase was transferred into a fresh tube, administered
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with 500µl of isopropyl alcohol and incubated for 10 minutes at room temperature. It was
then centrifuged for 10 minutes at 13,000rpm; 40C and observed a gel like pellet which
was formed at the bottom of the tube. The supernatant was slowly decanted and 1ml of
80% ethanol was added to this RNA pellet. It was again centrifuged for 5 minutes at
13,000 rpm; 40C, the supernatant was again decanted and the sample was left for drying
for more than an hour at room temperature in the sterile hood. It was re-dissolved in
100µl of DEPC RNAse free water and incubated at 570C for 10 minutes. It was added
with 12µl of reaction buffer, 4µl of DNAse I and was incubated at 370C for 1 hour with
slight shaking. 100µl of Acid Phenol Chloroform was added to it and placed in ice for 10
minutes. The samples were gently mixed by hand and centrifuged for 5 minutes at 11,300
rpm. Then the upper aqueous phase was transferred into a fresh tube and precipitation of
the RNA was performed after addition of 12µl of 3 M sodium acetate, pH 5.5 and 560µl
of ice cold 100% ethanol and placing them in -800C for overnight. The next day, these
samples were centrifuged for 5 minutes at 13,000 rpm, the supernatant was decanted and
the sample was dried for more than an hour in a sterile hood at room temperature. The
obtained RNA was re-dissolved in 100µl of DEPC RNAse free water and was placed in 800C until use.

RNA quantification using Ribogreen reagent
The quantification of RNA in the sample after being extracted by the Trizol
method was performed by using the Quant-iTTM RiboGreen kit obtained from Life
Technologies. The TE buffer was diluted to 1x from the 20x provided in the kit and all
other dilutions were similar to the manual provided along with the kit. As it has been
specified that the final volume of experimentation in microplate instead of cuvettes to be
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200µl instead of 2µl. So 1x TE was used to dilute both ribogreen reagent and standard
RNA provided in the kit. All the standards and samples were made into triplicates in the
microplate so that the standard deviation of them could be exactly calculated with only a
minimal error and their average has been taken into consideration for the quantification
of RNA. The stock standard solution given in the kit was 100mg/ml, which was diluted to
2mg/ml and eventually to 100mg/ml which was considered as a low range assay. This
final stock solution was added as 0, 2, 10, 50, 100 µls in triplicates along with 100, 98,
90, 50, 0 µls of TE buffer and all of them with 100 µl of ribogreen reagent at the end to
obtain a final volume of 200 µl making those standards as blank, 1, 5, 25 and 50 ng/ml
concentrated. In all other wells, 98 µl of TE buffer was administered with 2 µl of the
sample in triplicates, finally with 100 µl of ribogreen to make all of them 200 µl. They
were then labelled properly and analyzed by using Gen6.1 software in the Synergy – H1
fluorescence microplate reader obtained from Biotek Instruments, Inc (Winooski,
Vermont, USA) setting a standard wavelength of excitation ̴ 480 nm and emission ̴ 520
nm, exported into excel sheet and calculated for a final quantification similar to the
Bradford Protein Assay. The whole process has been performed under very dim light and
no direct exposure to light to avoid photo bleaching of the working solution. In this assay,
the binding of ribogreen to the RNA present in the standard and sample was very critical
for providing accurate values. Quantification of RNA in the samples was very important
for estimating the RNA content in the samples, for an accurate dilution factor for
maintaining a minimal value equal for all the samples in order to get good peaks in the
RT-PCR.

Reverse transcription for obtaining cDNA
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The obtained concentrations of all the samples of 24 hour and 48 hour have been
equalized for each set to a make it 100ng to 1000ng concentration depending upon the
lowest value in the set. Then the RNA of each sample is diluted to a final concentration
of 30µl and from that only 7.5µl is used for the reverse transcription process. The
supermix iScript Reverse Transcription Supermix for RT-qPCR Cat#170-8841 obtained
from Bio-Rad has been diluted with nuclease free water as per the protocol for example
413µl of nuclease free water was added to 150µl of the supermix to dilute it before the
addition of RNA to it. Then 22.5µl of this mixture was administered to 7.5µl of the RNA
sample to each well for obtaining a final volume of 30µl per each well, as we need 5µl
each of the c DNA template for obtaining the forward template through PCR reaction
finally. As we have designed every sample to be in triplicates, we need 30 µl each well of
the c DNA for obtaining 5µl of the template for 3 wells for Surfactant – B and 3 wells for
β – Actin of the final PCR reaction plate. Bio-Rad icycler iQ PCR plates, 96 well was
used and the plate was sealed with CFX96 Optical Quality Sealing tape obtained from
Bio-Rad and placed in the CFX96 Bio-Rad Real Time PCR Machine for undergoing the
process of reverse transcription. The complete mix has been incubated in thermal cycler
by using the protocol in which the step was to undergo priming at a temperature of 25°C
for 5 minutes, followed by Reverse Transcription (RT) at a temperature of 42°C for 30
minutes and finally inactivating the RT at a temperature of 85°C for 5 minutes which is
usually followed cooling the plate for 30 minutes at a temperature of 4°C.

Real Time PCR analysis
After the conversion of the RNA to cDNA, we had to analyze the expression
levels of the cells with no drug and the cells added with various drugs. For this, we
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prepared two Mastermixes one each specific for Surfactant–B containing surfactant–B
primers and β–actin here which was used as the housekeeper gene for these set of
experiments having β–actin primers. So the Mastermix which consists of SsoAdvanced
Universal SYBR Green Supermix Cat# 172-5271 obtained from Bio-Rad which was
administered to the mastermix as 10µl per well, 1µl each of the forward and reverse
primers of specific protein (either surfactant – B or β – Actin) and finally made to 15µl of
the mastermix per each well by the addition of 3µl of water per well. So, this mastermix
is tapped at the bottom of the microfuge tube for thorough mixing. After spinning the
tube, 15µl of the surfactant – B mastermix is added to the first row and β – Actin
mastermix to the next row and so on arranging both of them alternatively for an easy
quantification. Then 5µl of the previously obtained template is added to each of the
triplicates of surfactant – B and β – Actin by pipetting up and down according to a predesigned arrangement of the plate setup.
This is the plate setup used for the 24 hour drug sample for performing RT- qPCR
analysis in which 1.1, 1.2, 1.3 were controls; 2.1, 2.2, 2.3 were treated with
betamethasone; 3.1, 3.2, 3.3 were treated with progesterone; 4.1, 4.2, 4.3 were
combination of betamethasone and progesterone; 5.2, 5.3 were terbutaline alone; 6.1, 6.2,
6.3 were combination of terbutaline and betamethasone; 7.1, 7.2, 7.3 were leptin alone;
8.1, 8.3 were combination of leptin and betamethasone. NTC were no template controls
for both surfactant–B and β – Actin.
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Figure 5: RT- PCR Plate schemes for all the PCR analysis experiments. The plate
scheme is as follows: 1 - control, 2 - betamethasone, 3 – progesterone, 4 - progesterone in
combination with betamethasone, 5 – terbutaline, 6 – terbutaline in combination with
betamethasone, 7 – leptin and 8 – leptin in combination with betamethasone. All the
above treatment groups are analyzed in triplicates.
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The plate was incubated in the thermal cycler by following the previously
designed protocol after performing many trials. First the gradient temperature has been
tested from 40°C to 52°C for 2 – 3 times from which there were good expression levels
and Cq values seen for the 48°C annealing temperature. We have even tried with 35
cycles to 50 cycles for obtaining a good quantification data. The final protocol followed
during the actual experiment for all the samples in triplicates was maintained at 95°C for
30 seconds for the polymerase activation and DNA denaturation, then the 3 step cyclic
process for 50 cycles in which the first step is denaturation at 95°C for 15 seconds
followed by 48°C of annealing for 30seconds and 60°C for 30 seconds for extension and
plate read. After this process is being repeated for 50 cycles, 65°C - 95°C 0.5°C
increment 2-5sec per step for obtaining the melt curve. Finally it is kept on hold at 4°C
until removed. After obtaining the data of the Cq values and the melt curves, graphs have
been plotted according to the data.
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Results
TLC analysis of lipids from lung cells in response to tocolytics:
Tables 2 and Table 3 show the mean Retention Factor (Rf) values of 24 hour drug
treated and 48 hour drug treated media analyzed for phospholipids present in it through
Thin Layer Chromatography technique by spotting the sample and standard lecithin or
sphingomyelin upon HPTLC plates. The retention factor is calculated for all the 4 bands
appeared upon the HPTLC plates after analyzing them at 625nm for all the samples
(triplicates) and also the standard spotted upon each plate. These values allow proper
comparison of the standard and the four bands of the sample for a clear differentiation of
the phospholipids, lecithin and sphingomyelin. NA represents not applicable as only 1
standard has been spotted on the plate. The average sample Rf values have been shown in
these tables. From this Rf analysis, we determined that the top band aligned most closely
with lecithin and the third band aligned more closely with sphingomyelin. Unfortunately,
the results were not an exact match owing to different Rfs for different plates. Mass
spectrometry will provide a more definitive identity in the future.
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Table 2: Retention Factor (Rf) values for 24 hour TLC
Treatment

Band 1

Band 2

Band 3

Band 4

STD L

STD S

Control

0.29

0.35

0.44

0.51

0.36

NA

Betamethasone

0.38

0.41

0.50

0.58

NA

0.46

Progesterone

0.35

0.40

0.49

0.56

0.35

NA

Betamethasone+
Progesterone

0.33

0.37

0.48

0.54

0.32

NA

Terbutaline

0.27

0.31

0.40

0.47

NA

0.38

Betamethasone+
Terbutaline

0.29

0.32

0.41

0.46

0.30

NA

Leptin

0.26

0.29

0.38

0.44

NA

0.36

Betamethasone+
Leptin

0.20

0.25

0.41

0.46

0.17

NA

Band 4

STD L

STD S

Table 3: Retention Factor (Rf) values for 48 hour TLC
Treatment

Band 1

Band 2

Band 3

Control

0.23

0.27

0.36

0.42

0.20

0.34

Betamethasone

0.22

0.26

0.35

0.41

0.21

NA

Progesterone

0.22

0.26

0.35

0.41

NA

0.34

Betamethasone+
Progesterone

0.36

0.40

0.48

0.55

NA

0.34

Terbutaline

0.30

0.36

0.46

0.54

0.27

NA

Betamethasone+
Terbutaline

0.27

0.34

0.44

0.53

NA

0.42

Leptin

0.28

0.33

0.41

0.50

0.29

NA

Betamethasone+
Leptin

0.09

0.17

0.31

0.49

0.09

NA
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To determine the effect of betamethasone and the tocolytics on lipid production
and secretion from lung cells, we performed TLC analysis of the lipids extracted from
cells treated with these drugs. The tocolytics and their concentrations used in this study
are shown in Table 1. The extracted lipids were separated on the HPTLC plates in an
organic solvent system along with the standards for sphingomyelin and lecithin
(phosphatidylcholine). Densitometric analysis of the four bands observed with each lipid
spot in all lanes was determined and secretion estimated as the optical density relative to
background. Secretion of the lipids from control cells was minimal at 24 hours (Figure 6).
Exposure to betamethasone significantly increased lipid secretion (Increase observed in
all the bands). Progesterone alone or in combination with betamethasone significantly
increased secretion when compared to betamethasone alone (Figure 7; p<0.05).
Terbutaline showed a significant increase over control but the addition of betamethasone
did not cause further increase. Leptin alone provoked 10 fold increase compared to
controls (p<0.05), but was much lower in the presence of betamethasone, though still
about a 4 fold increase over controls (p<0.05).
After treatment with the drugs for 48 hour, betamethasone was not found to cause
a significant increase in lipid secretion (Figure 8). There was no significant increase in
lipid secretion in response to progesterone or progesterone in combination with
betamethasone (Figure 9). Lipid secretion was increased at 48 hours compared to control
with terbutaline and addition of betamethasone decreased secretion to control levels.
Leptin appeared to have no significant effect on bands 1 and 2. In contrast band 3 was
decreased and band 4 appeared not to be affected (Figure 9).

36

Band 1
Band 2
Band 3
Band 4

Band 1
Band 2
Band 3
Band 4

Figure 6: HPTLC analysis of Secreted Lipids from Lung Cells. Both of them are 24 hour drug
added treatment groups. Lipids were extracted from the media, separated by HPTLC plates, and
1.5 cm from the top of the plate. Each plate represents three independent samples from
experiments. Standard and samples have been prepared at same concentrations, however
evaporation in the mixture may have resulted in different final concentrations. In the figure, C control, B - betamethasone, P - progesterone, T - terbutaline, L - leptin.
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Figure 7: This graph represents the densitometric calculation of the bands of different
treatment groups obtained relative to the background through HPTLC’s for 24 hour drug
addition to those cells. The results represent the mean ± SEM for 3 independent wells of
cells treated individually. (* implies a significant increase in all the four bands combined
together compared to the control, ** implies a significant increase when compared to *)
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Band 1
Band 2
Band 3
Band 4

Band 1
Band 2
Band 3
Band 4

Figure 8: HPTLC analysis of Secreted Lipids from Lung Cells, 48 hours after treatment.
Lipids were extracted from the media, separated by HPTLC plates, and fluorescent
images captured at 465 nm (The samples were loade
from the top of the plate. Each plate represents three independent samples from
experiments.
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Figure 9: This data represents the densitometric calculation of the bands of different
treatment groups obtained relative to the background through HPTLC’s for 48 hour drug
addition to those cells.

Immunocytochemistry
Having observed a positive effect of the betamethasone, tocolytics and leptin on
lipid production and secretion. We wanted to determine if the above mentioned drugs
have a similar effect on intracellular surfactant – B secretion and production. To
determine the effect of each of the drug treatments on surfactant in the cells, we used
immunostaining with an antibody to surfactant-B protein. The cells which were
administered with the drugs for either 24 hours or 48 hours were probed with an antibody
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for surfactant along with DAPI reagent for staining the nuclei. Images were captured on
the fluorescent microscope. At 24 hours, it appeared that betamethasone-treated cells
showed an apparent increase in fluorescence signal relative to control cells (Figure 10).
At 24 hours, it appeared that betamethasone in combination with progesterone gave a
stronger response.

On the contrary, terbutaline and leptin both showed increased

brightness without betamethasone, which appeared to diminish in the presence of
betamethasone. In contrast, the images of 48-hour drug addition gave slightly different
results in that the surfactant content was marginally increased (Figure 11). We performed
the immunocytochemistry of these cells three times to ensure that the results were
reproducible. Altogether, these results suggest that betamethasone with progesterone
have a positive influence on surfactant-B production.
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Figure 10: The above figure shows the microscopic view of the fluorescent light upon
these cells of H441 adenocarcinoma cells which shows an increase in the brightness or
intensity of the lipids after 24 hours of various drug addition to each of them when
compared to the control and the positive control, betamethasone (BMS).
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Figure 11: The above figure shows the microscopic view of the fluorescent light upon
these cells of H441 adenocarcinoma cells which shows an increase in the brightness or
intensity of the lipids after 48 hour of various drug addition to each of them when
compared to the control and the positive control, betamethasone (BMS).
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Western blotting
Immunocytochemistry is a visual observation type of analysis and can be very
subjective depending upon the eyes of the observer, difference in production of protein
and lipids among different sets of experiments, number of cells and other factors.
Therefore, we used western blotting to determine the effects of the above mentioned
drugs on SP-B expression on NCI-H441 cells. Western blotting was completed on the
protein in the cells and media and then analyzed densitometrically through image lab
software. 24 hour treated cell extracts have shown a profound band for SP-B at ̴ 38 kDa
and a doublet band for β-actin at ̴ 42 kDa (Figure 12A). This might strongly be the
difference between the protein content (baseline) between different treatment groups in
different sets of experiments, which may have caused a bigger standard error, more
variability between treatment groups, change in culture conditions and all other
uncontrollable factors may have contributed for not showing any significant difference
between any of the treatment groups, which can be evident through the individual graphs
of different sets measured quantitatively.
At 48 hours, there was a less distinguished band for control and betamethasone
treated SP-B, showing a reduction in SP-B expression and also β-actin when compared to
the 24 hour control and betamethasone-treated cells (Figure 12B). When the density of
each band for each of the treatment groups was analyzed, there appeared to be no
significant difference in surfactant-B production at 24 and 48 hours (Figures 13 & 14).
The western blot results appear to suggest that SP-B is not significantly affected with any
of the drugs used in this study, due to many factors affecting its actual result.
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Figure 12: Western blot analysis of surfactant–B and actin in extracts of cells treated
with tocolytic agents at (A) 24 hours of treatment with all those drugs for surfactant-B
protein found at ̴ 38 kDa and β-actin protein at ̴ 42 kDa (B) 48 hours of drug treatment for
surfactant-B protein and β-actin protein .
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Figure 13: Densitometric analysis of the surfactant bands from 24 hour treatment groups.
Surfactant density was normalized to b-actin for statistical analysis. The results represent
the mean ± SEM from 3 different determinations for each treatment group or control.

Figure 14: Densitometric analysis of the surfactant bands from 48 hour treatment groups.
Surfactant density was normalized to b-actin for statistical analysis. The results represent
the mean ± SEM from 3 different determinations for each treatment group or control.
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Leptin receptor protein
The first question to be answered about leptin receptors was whether leptin
receptor protein was present in the NCI441 cells (mature cells) used in this project.
Western blot analysis of the cell lysates showed a faint but discernible band at 150 kDa as
predicted for the leptin receptor (Figure 15 A&B). Although we cannot initiate the
receptor protein abundance in-vitro, we have tried to see if there was any difference in the
receptor protein content after addition of these drugs, as there may be a modification in
the protein due to the mRNA changes and other expressions of the cells in presence of
these drugs.
After 24 hours of drug treatment, there appeared to be a slight increase in leptin
receptor expression in response to betamethasone (Figure 15). In the other treatment
groups it appeared as though the 150 kDa band was shifted to a smaller size, ̴ 100 kDa
and the other as ̴ 75 kDa. The beta actin doublet was also present. At 24 hours, the bands
were faint and densitometric analysis suggested that there may have been a drug effect,
but there was no significant difference due to high variability in different blots.
For 48 hours of drug treated cells, the results were even less pronounced as the
bands were barely visible and have made the densitometric analysis very difficult. But by
observing the western blots of all the sets of 48 hour drug treated cells have shown either
a degradation of protein or the cleavage of the protein. This is because of the appearance
of bands at three different molecular weights as mentioned above. This has made even
difficult for densitometric analysis, as these degradations were not observed with all the
treatment groups repetitively with the same group in all the sets of experiments. Hence
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made this a big problem for their densitometric analysis for considering only one
prominent band and this led for a greater statistical error for their comparison with the
control, though observed by the naked eye. Overall, the results made it difficult to
determine anything except that the leptin receptor protein appeared to be present in these
mature cell line and proved that they are not only confined to the fetal cell line.

Figure 15. Representative images for the leptin receptor protein and beta-actin protein
obtained through western blotting. (A) 24 hour treatment with the tocyolytics for leptin
receptor protein observed at ̴ 150 kDa and cleavage or degradation of protein at ̴ 100 kDa
and β-actin protein at ̴ 42 kDa (B) represents 48 hour treatment with above mentioned
drugs for leptin receptor protein observed at ̴ 150 kDa and β-actin protein at ̴ 42 kDa.
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Figure 16: Densitometric analysis of the leptin bands from 24 hour treatment groups.
Leptin density from the western blot was normalized to b-actin for statistical analysis.
The results represent the mean ± SEM from 3 different determinations for each treatment
group or control

Figure 17: Densitometric analysis of the leptin bands from 48 hour treatment groups.
Leptin density was normalized to b-actin for statistical analysis. The results represent the
mean ± SEM from 3 different determinations for each treatment group or control.
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Real Time - PCR Analysis
Next we analyzed the SP-B mRNA expression. At 24 hours, the RT-PCR showed
curves for most of the wells from surfactant-B and β-actin primers. Although a high
amount of template was used (990ng) for all sets of experiments of 24 hour drug treated
cells with PCR, the curves which are obtained during the quantification of the template
by using a Bio-Rad’s software for PCR analysis has shown a shift of these curves to the
right, suggesting the presence of low amount of mRNA in the template. The curves of
actin were similar to the surfactant-B suggesting that the RNA may have been degraded.
At 48 hours, the amount of mRNA that could be used for a template was much
lower resulting in the shift of those curves further to the right. This shift pushed the PCR
to give curves at or after 50 cycles, preventing us from using the data for ∆∆CT analysis.
Hence we can say that the results of 48 hours of drug addition were not significant as
determined by statistics with a p<0.05 and cannot be considered for final evaluation.
The results from the drug treatment at 24 hours show significant increase in
surfactant-B mRNA with the addition of betamethasone versus control, progesterone, and
leptin respectively. Progesterone in combination with betamethasone has shown a
significant increase when compared to progesterone alone. Leptin with betamethasone
has also shown a significant decrease in surfactant-B mRNA when compared to
betamethasone alone. These results suggest that Leptin Receptor mRNA is expressed in
the mature lung cell line and that it is responsive to betamethasone and other tocolytic
treatments.
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Figure 18: Images obtained through Real time PCR analysis for quantification of
expression levels and mRNA secretion of surfactant-B by addition of 24 hours of
Control, Betamethasone, Progesterone and Progesterone

in combination with

betamethasone, the positive control (samples 1.1 -4.3 as shown in the plate setup,
analyzed in triplicates) A. Shows curves obtained with Surfactant-B primers and B.
Shows curves obtained with Beta-Actin primers.
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Figure 19: Images obtained through Real time PCR analysis for quantification of
expression levels and mRNA secretion of surfactant-B by addition of 24 hours of
terbutaline, terbutaline in combination with betamethasone, leptin alone and in
combination with betamethasone (Samples 5.2 -8.3 as shown in the plate setup, analyzed
in triplicates) A. Shows curves obtained with Surfactant-B primers and B. Shows curves
obtained with Beta-Actin primers.
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Figure 20: CT analysis of qRT-PCR results for lung cells treated with different
tocolytics. Here the Y-axis represents the relative change according to the 2^-DDCT
results and X-axis represents the treatment groups. (* is a significant difference observed
when compared to control, progesterone and leptin respectively from left to right)
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Figure 21: Image obtained through Real time PCR analysis for quantification of
expression levels and mRNA secretion of surfactant-B by addition of 48 hours of control,
betamethasone, progesterone, progesterone in combination with betamethasone (Samples
1.1 -4.3 as shown in the plate setup, analyzed in triplicates) A. Shows curves obtained
with Surfactant-B primers and B. Shows curves obtained with Beta-Actin primers.
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Figure 22: Image obtained through Real time PCR analysis for quantification of
expression levels and mRNA secretion of surfactant-B by addition of 48 hours
terbutaline, terbutaline in combination with betamethasone, leptin alone and in
combination with betamethasone (Samples 5.2 -8.3 as shown in the plate setup, analyzed
in triplicates) A. Shows curves obtained with Surfactant-B primers and B. Shows curves
obtained with Beta-Actin primers.
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Figure 23: This image above represents the 48 hour of drug addition and the DCT
analysis of qRT-PCR results for lung cells treated with different tocolytics. Here the Yaxis represents the relative change according to the 2^DCT calculations and X-axis
represents the treatment groups. The actin did not have a valid CT value in most cases to
accurately allow a DDCT analysis. The results represent the mean ± SEM from three
independent wells of cells.

∆∆CT analysis was performed for only the 24 hour calculation of expression
levels and mRNA secretion in the human alveolar type-II cells, as there was no ß - actin
available for the comparision in case of the 48 hour tests. The house keeper gene has not
shown any variability in the peaks nor have shown good peak unlike the primers for
Surfactant B have shown, for comparative quantification the surfactant B peaks with the
ß-actin. So, for this reason we have calculated the ∆CT calculation which compares the
surfactant – B peaks with the other drugs.
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Discussion
Oftentimes, one of the first steps to testing the safety and efficacy of a drug or a
combination of drugs is to screen them using an in-vitro cell culture system, or cell line.
While it is known that cell lines are not an exact match to ‘normal’ or primary cells, they
do often share adequate similar characteristics with primary cells that allows a first pass
mechanism for screening. In the project presented here, we have used a human lung
adenocarcinoma epithelial cell line, NCI-H441, as a reliable in vitro model to test three
drugs that are commonly used to either help in fetal lung maturity, delay the contractions
of labor and preterm birth or both (33, 34, 35). These drugs are betamethasone, a
corticosteroid that is used to mature fetal lungs; progesterone, a steroid hormone that is
used to slow contractions, and terbutaline, a beta-agonist that is purported to slow
contractions and also mature the lungs. We also have tested a peptide hormone that is
secreted by adipose tissue, i.e., leptin, for its ability to mature lungs and increase
surfactant production. The goal of using the above-mentioned drugs in preterm birth is to
slow the contractions for one to two days in order to allow the betamethasone to work in
increasing surfactant secretion from the lungs of the fetus. The overall idea is that after
administration of these drugs, birth of the infant can occur and respiratory distress
syndrome can mostly be avoided. However, few studies have been performed to
determine the effect of some of these drugs on the lung cell production of surfactant and
lipids. Therefore, the main aim of this project was to determine if each of the drugs would
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cause an increase in surfactant production in the cells and lipid secretion from the cells.
We tested each drug alone and in combination with betamethasone in our cell culture
model using: High Performance TLC analysis of lipids secreted; immunocytochemistry
and western blotting for surfactant-B production; and Real Time PCR to analyze the
surfactant-B mRNA levels after treatment.

Betamethasone stimulates lipid secretion and surfactant-B production
We first tested whether betamethasone would stimulate lipid secretion and
surfactant-B production in this NCI-H441 cells. HPTLC analysis revealed that
betamethasone stimulated lipid release from the cells at 24 hours. The results also suggest
that the top band was most probably lecithin, since it ran on the TLC plate at a similar
retention value (Rf) compared with the standard for lecithin run at the same time.
Furthermore, it has previously been reported that under similar running conditions,
lecithin ran ahead of sphingomyelin, which does correlate with our results of the
standards (68). However, the identity of the bands will require further analysis by mass
spectrometry to determine the true identity of each band, as either authentic lecithin or
sphingomyelin, or their metabolites. Finally, secretion of the top band was consistently
stimulated by betamethasone whereas, the other bands were less stimulated. The
immunocytochemistry strongly supported the betamethasone effect by showing a very
large increase in surfactant-B immunostaining after administering it to the cells. In
addition, Real Time PCR showed a similar trend where surfactant B mRNA was
stimulated with the addition of betamethasone. These results are similar to other studies
that showed this cell line reacted similarly by causing an increase in expression levels of
SP-B mRNA (69).
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In contrast, the western blot analysis of cellular surfactant-B did not show a
significant increase after addition of betamethasone. The large variability in the western
blot data could possibly be explained in several ways. First the only protein band we
observed was at ~38 kDa, which corresponds to the full-length size of pro-surfactant-B.
However, the antibody was not designed to detect the 9 kDa band of mature surfactant B.
If surfactant-B is stimulated to overproduce and only a small amount of the pro-form of
surfactant-B is cleaved to the mature form, it may be difficult to detect a change even in
the larger pro-form. Likewise, secretion of mature surfactant-B and pro-surfactant-B may
have caused a significant decrease in the signal in the cell lysates. Preliminary
experiments results using the media from the cells at the time of harvest did not show a
38 kDa band for surfactant-B protein nor a band for the mature form, suggesting that both
forms might not be secreted. A more thorough analysis of the cell lysate and media
protein content using ELISA for the mature 9kDa peptide would provide a better picture
of the effects that betamethasone has on these cells.
In contrast, at 48 hours, there was a general higher secretion of lipids including
from the control cells to the point that there was no significant Betamethasone
stimulation. The immunocytochemistry and western blots results confirmed these results,
though again, there was too much variability to make a definite conclusion. Real Time
PCR was not conclusive as many of the PCRs failed due to low RNA extraction from the
cells at 48 hours.

Progesterone
Progesterone is commonly used to slow contractions due to its effect on
suppressing the calcium-calmodulin-myosin light chain kinase system by reducing the
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calcium influx into the epithelial membrane and altering the resting potential of smooth
muscle (45). In our study, we found that progesterone had a significant effect on lipid
secretion, compared to control cells. In particular, the top, presumably lecithin band in
the HPTLC plates appeared to be stimulated with progesterone alone, and was augmented
with betamethasone. Likewise, we observed that the immunocytochemical staining was
very similar between progesterone and progesterone in combination with betamethasone.
The Real Time PCR analysis of the surfactant B mRNA expression was low in
progesterone treated cells when compared to controls but was significantly increased with
the addition of betamethasone in combination with progesterone. These results are similar
to previous studies that there was a marked increase in surfactant proteins due to
progesterone (43). As with the control and betamethasone alone treated cells before,
western

blots

failed

to

show

significant

differences

for

progesterone

and

progesterone/betamethasone treated cells. At 48 hours there appeared to be no significant
difference in lipid secretion, surfactant B staining or proteins on western blots.
The results from our study suggest that progesterone in conjunction with
betamethasone could be a useful and effective treatment to both slow labor contractions
and stimulate lung maturation. Furthermore, the results suggest that progesterone in
combination could be a better short term, i.e., 24 hours, treatment.

Terbutaline
Terbutaline is an interesting ‘dual function’ drug because it relaxes the smooth
muscles to delay contraction and it is also used as a treatment for asthma as a betaagonist. Terbutaline’s effect on lipid secretion, especially band 1 lecithin, was slightly
higher or almost similar to that of progesterone’s at 24 hours. This result is supported by
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a study showing an increase in phosphatidylcholine (Lecithin) secretion in alveolar type
II cells (50). Immunocytochemistry showed an increased staining of SP-B after
administration of terbutaline both with and without betamethasone. Real Time PCR was
less satisfactory with a very large variability that made it impossible to draw any
conclusions. However, it appeared that there was a significant decrease in surfactant-B
mRNA expression between terbutaline + betamethasone and progesterone +
betamethasone at 24 hours of treatment. As usual, western blot analysis failed to show a
difference due to the high variability of the bands and β-actin staining. The results at 48
hours were similar to those at 24 hours with the exception that band 2 in the lipids was
significantly increased with betamethasone. While we have considered band 1 of the
HPTLC plates to be lecithin, we had not made a determination about the other bands, i.e.,
bands 2, 3, and 4, though we propose that band 3 is sphingomyelin. With terbutaline
treatment band 2 appeared to be significantly increased, and could have been a metabolite
of either lecithin or sphingomyelin. The difference in band 2 at 48 hours on HPTLC and
bands 1, 2, and 4 at 24 hours are consistent with previous reports of terbutaline
stimulating lecithin secretion and also increased expression of surfactant lipids as a whole
potentially due to the beta-agonist function of terbutaline, and not as a stimulator of
synthesis (50, 70). Terbutaline is considered a very short term treatment, i.e., <48 hours,
and our results suggest that that it does have effectiveness at this time point.

Leptin
The first question about leptin was whether there are leptin receptors in the lung
cells. There have been reports that different receptor isoforms are expressed in the lungs,
and that leptin itself is also expressed. We tested for the presence of the leptin receptor by
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western blot analysis in each of the samples from the stimulation experiments, as some
recent studies have confirmed the expression of leptin receptor by fetal rat lung type – II
cells and also by the NH441- human adult lung epithelial cells (73). Although there was a
weak band in the western blots, we were able to determine that there was a leptin receptor
in the lung cells. Leptin receptor protein was found at 150 k Da and 100 kDa
predominantly in many experiments, also showing a weak band at 75 kDa for some of the
drug treated cell lysates. These protein bands when probed by a specific anti-leptin
receptor protein primary antibody suggests that the receptor might have been posttranslationally modified by an enzymatic cleavage or have undergone degradation. Future
experiments will determine if another receptor isoform predominates in these cells.
Although leptin is not considered a tocolytic, it has been proposed to have an
effect on lipid and surfactant secretion in the lung. In our study, leptin caused a profound
stimulation on the secretion of lipids, specifically bands 1 and 2, after 24 hours of
treatment. This result was similar to the result obtained by Torday et al showing that
leptin plays a role in stimulating the de nevo synthesis of surfactant phospholipid
particularly in H441 cells and also fetal rat lung type II cells (73). Cellular staining of SPB also appeared to be brighter with leptin as well as with leptin + betamethasone. The
RealTime PCR results showed a very dramatic decrease in mRNA at 24 hours with leptin
treatment when compared to betamethasone, but not a significant decrease in mRNA with
when compared to control. However, the combination of leptin and betamethasone did
appear to cause stimulation of surfactant B mRNA, though it was still low. These results
suggest that leptin may play a role in surfactant gene regulation in the lungs. In previous
studies, it has been shown that the expression of surfactant – B protein in some cell lines
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including NCI441 cells was modestly increased by the presence of glucocorticoids and
also that the expression of SP-B gene would primarily be controlled at the posttranscriptional level than directly by the gene transcription (74, 75, 70, 71). It also
suggests that women who are producing a large amount of leptin naturally may also be
suppressing the surfactant gene expression in the fetus and hence there is a propensity for
problems associated with obesity as well as having a lower body weight or BMI. Thus,
leptin may be playing a larger role than first previously thought. This is similar with
results obtained using rat primary alveolar cells that also showed a reduction in surfactant
B mRNA and protein by western blots (72, 73). In another study, leptin was found to
cause an increase in fetal lung cell surfactant B mRNA and protein (18), though it
appeared to be temporally regulated to a very small window of gestation (52, 76). The
authors postulated that other cell interactions, e.g., clara cells, may be involved in
regulating the expression of surfactant B in response to leptin (18). It has also been
proposed by Waddell et al (2003) that the plasma leptin binding sites may occasionally
contribute to restrict the access of leptin to target tissues, suggesting that the soluble
leptin receptor isoform may sometimes effect the transportation and metabolism of leptin,
during pregnancy (77 – 79). Another study has postulated that androgens might
contribute to inhibit the surfactant production with an addition of leptin, which backs up a
slight decrease of SP-B mRNA in the study when compared to betamethasone treated
cells, as we have used adenocarcinoma type – II cells of male adult obtained from ATCC
(80).

63

Western Blot Problems
There was a small difference in the protein content of β-actin when compared to
the specific-protein (surfactant-B). This is due to the fact that the same PVDF membrane
has been used for detecting the protein bands of surfactant-B and then stripped with a
stripping buffer for analyzing for the total protein content. Though we are aware that
stripping procedure causes a slight decrease in the protein content, by stripping some of
the protein content along with the antibodies. They have been stripped to detect the
proteins at different molecular weights upon the same PVDF, so that we can exactly
prove that the proteins are specifically detected with the addition of their specific
antibodies (to confirm that they are not non-specific proteins). It is interesting to note that
surfactant B is a 40 kDa pro-protein that is cleaved intracellularly to a 9 kDa peptide that
can homodimerize with itself. This combination would give a peptide of 18kDa. We did
not observe any of the 18 kDa peptides on the western blots, suggesting that the
surfactant B was mostly in its pro-form. We have also never observed a smaller
surfactant B peptide, i.e., 9 kDa in these cells, further suggesting that the enzyme that
cleaves it is either missing defective or very inactive.
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Conclusions
The objective of this study was to determine if adult human lung cells could be
used to study the effects of different drugs on lipid secretion and surfactant-B production.
We have shown results similar to previous reports that lipid secretion does respond to
betamethasone, progesterone, terbutaline, and leptin in these cells. Furthermore, mRNA
levels and immunocytochemistry appeared to confirm the lipid profile suggesting that
these therapies may be used as previously reported. Our results support the continued use
of progesterone alone as a tocolytic or in conjunction with betamethasone for its ability to
help mature the lungs. However, the results also suggest that leptin may play a role in
regulating surfactant production and surfactant mRNA expression that has previously
been unexplored. Further research in this area as well as the longer-term use of
terbutaline is necessary to provide insight into the mechanisms for these types of drugs
and as a precursor to designing and testing better tocolytics in the future.
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Future studies
It appears that all of the tocolytics except progesterone in combination with
betamethasone, may be further tested before performing future clinical work. Factors
potentially affecting the mechanisms involved in the functioning of these drugs should be
identified including genetic factors, growth factors and inhibitory mechanisms which are
coming into play during the development of the lung. In addition, in vivo effects of these
drugs on surfactant production should be identified for a thorough mechanistic
explanation.
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